Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cheek

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Cheek. Displaying page 1 of 1.
    EudraCT Number: 2004-004074-93 Sponsor Protocol Number: EP005 Start Date*: 2005-03-01
    Sponsor Name:EpiTan Limited
    Full Title: A Pilot, Phase II, Open, Controlled Study to Evaluate the Safety, Tolerability and Efficacy of a Subcutaneous Implant of Melanotan in Patients Suffering from Recurrent Polymorphous Light Eruption.
    Medical condition: Polymorphous Light Eruption (PMLE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003707-40 Sponsor Protocol Number: RD.03.SPR.40031 Start Date*: 2007-01-09
    Sponsor Name:Galderma Research and Development SNC
    Full Title: Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea.
    Medical condition: Erythemato-Telangiectatic Rosacea (ETR)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039218 Rosacea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-013111-35 Sponsor Protocol Number: RD.03.SPR.40099E Start Date*: 2009-12-23
    Sponsor Name:Galderma R&D SNC
    Full Title: EFFECT OF CD08514 VERSUS PLACEBO, IN PATIENTS PRESENTING WITH TYPE 1 ROSACEA, OVER AN 8-WEEK TREATMENT
    Medical condition: Moderate to severe erythematotelangiectactic rosacea (ETR)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039218 Rosacea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006252-19 Sponsor Protocol Number: 1.0. Start Date*: 2008-07-24
    Sponsor Name:Univ.-Prof. DDr. Norbert Jakse, Universitätszahnklinik Graz, Dep. f. Orale Chirurgie u. Röntgenologi
    Full Title: Einfluss von peroraler Methylprednisolon-Gabe auf die postoperative Morbidität nach operativer Weisheitszahnenfernung im Unterkiefer. (Influence of peroral Methylprednisolone administration on the...
    Medical condition: To be investigated is the anti-inflammatory and anti-oedematous effect of methylprednisolone on the postoperative sequelae after surgical removal of lower third molars. 16 healthy patients will und...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011819-20 Sponsor Protocol Number: V00067 CA 201 1A Start Date*: 2009-05-29
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study.
    Medical condition: Adult patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome, with implantable cardioverter defibrillator (ICD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057926 Long QT syndrome congenital LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000034-36 Sponsor Protocol Number: CHDR1734_CLS003-CO-PR-004 Start Date*: 2018-08-10
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, double blind, vehicle controlled, parallel group study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT), comprised of digoxin...
    Medical condition: Actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002699-98 Sponsor Protocol Number: CB001-OL Start Date*: 2015-04-14
    Sponsor Name:University of Oxford
    Full Title: OxLith: Exploration of the short-term physical and psychological effects of lithium in mood instability
    Medical condition: Bipolar disorder with current mood instability
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10004908 Bipolar affective disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001714-96 Sponsor Protocol Number: R2222-RSV-1332 Start Date*: 2015-11-03
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in ...
    Medical condition: Medically attended respiratory syncytial virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Preterm newborn infants, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) HU (Completed) FI (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000066-29 Sponsor Protocol Number: RD.03.SPR.114384 Start Date*: 2017-05-15
    Sponsor Name:Galderma R&D
    Full Title: Subject reported outcomes on satisfaction, efficacy and safety with Luxerm® in the field-directed treatment of thin or non-hyperkeratotic and non-pigmented Actinic Keratosis of the face or the scalp
    Medical condition: Thin or non-hyperkeratotic and non-pigmented Actinic Keratosis on the face and scalp
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10020648 Hyperkeratoses HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009463-61 Sponsor Protocol Number: MD2009.01 Start Date*: 2009-08-06
    Sponsor Name:Sanquin Plasma Products
    Full Title: Controlled trail of immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial parvovirus B19 persistence - - a prospective, double-blind, randomized, placebo-controlled...
    Medical condition: PVB19 mediated cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056419 Dilated cardiomyopathy LLT
    9.1 10034099 Parvovirus B19 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004651-36 Sponsor Protocol Number: GlibforCS Start Date*: 2021-05-21
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: Glibenclamide Treatment for Cantú syndrome
    Medical condition: Cantú syndrome
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000490-20 Sponsor Protocol Number: Galderma-Metvix Start Date*: 2018-02-08
    Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli"
    Full Title: Evaluation of efficacy, safety and patient¿s satisfaction of daylight photodynamic therapy (DL-PDT) in the treatment of actinic keratosis on the face and scalp and related field cancerization carri...
    Medical condition: actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064679 Basal cell carcinoma of skin in situ LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    21.0 10040785 - Skin and subcutaneous tissue disorders 10064266 Skin hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019952-35 Sponsor Protocol Number: CS001P3 Start Date*: 2010-09-14
    Sponsor Name:CEL-SCI Corporation
    Full Title: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemorad...
    Medical condition: Subjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft Palate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) RO (Ongoing) HR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004338-13 Sponsor Protocol Number: 2013_36 Start Date*: 2014-12-08
    Sponsor Name:CHRU De Lille
    Full Title: Phase II study evaluating the interest of Vismodegib as neo-adjuvant treatment of basal cell carcinoma
    Medical condition: Male and female patients at least 18 years of age with histologically confirmed diagnoses of locally advanced BCC
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005555-80 Sponsor Protocol Number: V00400SB302 Start Date*: 2015-05-21
    Sponsor Name:Pierre Fabre Dermatologie represented by IRPF
    Full Title: Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational Single Arm Study
    Medical condition: High risk infantile haemangioma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018814 Haemangioma PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 15:26:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA